Krystal Biotech, Inc. (KRYS)

Market Cap	5.11B
Revenue (ttm)	241.52M
Net Income (ttm)	52.37M
Shares Out	28.76M
EPS (ttm)	1.77
PE Ratio	100.17
Forward PE	37.76
Dividend	n/a
Ex-Dividend Date	n/a

Volume	84,081
Open	174.30
Previous Close	175.64
Day's Range	173.65 - 178.49
52-Week Range	99.00 - 219.34
Beta	0.82
Analysts	Strong Buy
Price Target	206.00 (+15.98%)
Earnings Date	Nov 4, 2024

About KRYS

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cys...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Sep 20, 2017
• Employees: 229
• Stock Exchange: NASDAQ
• Ticker Symbol: KRYS
• Website: https://www.krystalbio.com

Analyst Forecast

According to 7 analysts, the average rating for KRYS stock is "Strong Buy." The 12-month stock price forecast is $206.0, which is an increase of 15.98% from the latest price.

Price Target

$206.0

(15.98% upside)

Analyst Consensus: Strong Buy